StockData
Arcus Biosciences, Inc. logo

Arcus Biosciences, Inc. (RCUS) company profile

RCUSNYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 3/30123% above fair value
$16.39−0.47 (-2.79%)

Close on Nov 17, 2026Market cap $2.09BP/E –Yield –

About Arcus Biosciences

Pharmaceutical Preparations, SIC 2834

Arcus is a clinical-stage biopharmaceutical company that develops small-molecule therapies and antibodies for patients with cancer and autoimmune or inflammatory diseases. Its primary oncology pipeline includes casdatifan, an oral HIF-2α inhibitor for kidney cancer; quemliclustat, a CD73 enzyme inhibitor for pancreatic cancer; domvanalimab, an anti-TIGIT antibody for lung cancer; and zimberelimab, an anti-PD-1 antibody. The company also pursues preclinical research targeting inflammatory conditions such as chronic urticaria and atopic dermatitis. Its end users are individuals with these oncologic and inflammatory disorders.

Regarding scale and geography, the company maintains a worldwide patent estate containing more than 850 granted or pending patents, including 41 issued United States patents. Its clinical evaluations span multi-regional trials, with zimberelimab tested in over 2,600 patients. Commercialization and licensing agreements cover global territories, including the United States, alongside Japan and other Asian markets excluding China. The business does not operate internal manufacturing or storage facilities, relying instead on third-party contract manufacturers. Its corporate headquarters location is not stated in the text.

Summary of the business section of Arcus Biosciences's latest annual report, written by StockData.

Company profile

Company

Legal name
Arcus Biosciences, Inc.
Founded
2015
Headquarters
Hayward, CA
Address
3928 Point Eden Way 94545
Phone
(510) 694-6200
Employees
601, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young, LLP, San Mateo, California

Stock & identifiers

Ticker
RCUS
Exchange
NYSE
IPO date
Mar 16, 2018
Shares outstanding
127M, Jul 30, 2026
Public float
$565.88M, Jun 30, 2025
Filer category
Large accelerated filer
SEC CIK
1724521
CUSIP
03969F109
ISIN
US03969F1093
FIGI
BBG00DQD26W3
Share class FIGI
BBG00DQD2751
LEI
213800CSKAC96ELS4K25
EIN
47-3898435

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Terry J. RosenChief Executive Officer, Director5,670,279
Alexander AzoyChief Accounting Officer39,581
Juan C. JaenPresident1,200,799
Carolyn C. TangGeneral Counsel184,607
II Robert C. GoeltzChief Financial Officer84,161
Richard MarkusChief Medical Officer89,647
Jennifer JarrettChief Operating Officer224,024
Dimitry SA NuytenChief Medical Officer87,518
Patrick MachadoDirector44,300
Nicole LambertDirector43,000
Antoni RibasDirector52,853
David L. LaceyDirector76,652
Andrew J. PerlmanDirector48,325
Kathryn E. FalbergDirector176,406
Yasunori KanekoDirector957,955
Dietmar BergerDirector0

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$9.66M$17.73M$3.55M$90$88
FY2024$7.28M$4.80M$2.79M$147$95
FY2023$10.12M$7.48M$4.19M$194$94
FY2022$9.05M-$2.07M$4.19M$205$88
FY2021$9.48M$14.58M$5.94M$401$118
FY2020$5.69M$12.02M$5.36M$257$148

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsIncentive payOtherTotalvs. prior year
Terry Rosen, Ph.D.
Chief Executive Officer and Director
$775.00K–$2.20M$6.01M$658.75K$14.75K$9.66M+33%
Robert C. Goeltz, II
Chief Financial Officer
$540.00K–$493.21K$1.39M$243.00K$9.69K$2.67M+32%
Juan Carlos Jaen, Ph.D.
President
$660.00K–$666.50K$1.85M$330.00K$15.54K$3.52M+6%
Jennifer Jarrett
Chief Operating Officer
$660.00K–$666.50K$1.85M$330.00K$10.82K$3.52M+6%
Richard Markus, M.D., Ph.D.
Chief Medical Officer
$552.31K$100.00K$936.15K$2.64M$270.00K$11.58K$4.51M–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Mar 16, 2018
Offer price
$15.00
Securities offered
8,000,000
Gross proceeds
$120.00M
Exchange
NYSE
First trading day
Mar 15, 2018
First-day close
$17.00+13.3%
Lock-up ends (est.)
Sep 11, 2018

“The initial public offering price is $15.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 601 full-time employees, approximately 49% of whom hold Ph.D., M.D., R.N., or similar degrees and certifications.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?